DJI46,946.41+0.83%
GDAXI23,564.01+0.50%
GSPC6,699.38+1.01%
HSI26,107.88+1.06%
IXIC22,374.18+1.22%
N22554,013.73+0.49%
AAPL252.82+1.08%
AMZN211.74+1.96%
CL96.01+2.68%
EURUSD1.1505-0.04%
GBPUSD1.3313-0.05%
GC5,034.00+0.64%
GOOG304.42+0.98%
JPM286.16+0.96%
META627.45+2.33%
MSFT399.95+1.11%
NVDA183.22+1.65%
TSLA395.56+1.11%
DJI46,946.41+0.83%
GDAXI23,564.01+0.50%
GSPC6,699.38+1.01%
HSI26,107.88+1.06%
IXIC22,374.18+1.22%
N22554,013.73+0.49%
AAPL252.82+1.08%
AMZN211.74+1.96%
CL96.01+2.68%
EURUSD1.1505-0.04%
GBPUSD1.3313-0.05%
GC5,034.00+0.64%
GOOG304.42+0.98%
JPM286.16+0.96%
META627.45+2.33%
MSFT399.95+1.11%
NVDA183.22+1.65%
TSLA395.56+1.11%
DJI46,946.41+0.83%
GDAXI23,564.01+0.50%
GSPC6,699.38+1.01%
HSI26,107.88+1.06%
IXIC22,374.18+1.22%
N22554,013.73+0.49%
AAPL252.82+1.08%
AMZN211.74+1.96%
CL96.01+2.68%
EURUSD1.1505-0.04%
GBPUSD1.3313-0.05%
GC5,034.00+0.64%
GOOG304.42+0.98%
JPM286.16+0.96%
META627.45+2.33%
MSFT399.95+1.11%
NVDA183.22+1.65%
TSLA395.56+1.11%
CYBERETIKAGLOBAL FINANCIAL INTELLIGENCE
LIVE
GBR City AM EN

Waiv Secures $33 Million to Scale AI Precision Testing

Waiv, a Paris-based startup, spins out of Owkin to accelerate AI-enabled precision oncology testing

Mar 12, 2026 &03441212202631; 15:44 UTC www.cityam.com
Read original on www.cityam.com ↗
↗
Positive for markets
Sentiment score: +65/100
Moderate impact Medium-term (weeks)
WHAT THIS MEANS
Waiv, a Paris-based AI precision oncology testing startup spun out from Owkin, has secured $33 million in funding to scale its operations. This capital injection supports the expansion of AI-enabled diagnostic testing in the oncology sector, positioning the company for accelerated growth in precision medicine.
AI CONFIDENCE
75% High
SENTIMENT GAUGE
NEWS POWER SCORE
AFFECTED ASSETS
↑
OWKIN
OWKINStock
Expected to rise
Parent company benefits from successful spinout validation and continued innovation in AI-driven healthcare diagnostics
↑
EU→.PA
EU→.PAIndex
Expected to rise
French biotech and AI sector receives positive sentiment from significant funding round in precision medicine
↑
Euro Stoxx 50
^STOXX50EIndex
Expected to rise
European healthcare and technology sectors benefit from innovation in AI-enabled oncology diagnostics
PRICE HISTORY
Loading chart...
⚡ SUGGESTED ACTION
Monitor Owkin's stock performance as validation of its biotech innovation pipeline. Consider exposure to European biotech and AI healthcare companies benefiting from precision oncology market growth, particularly through indices like STOXX50E or direct positions in French healthcare innovators.
KEY SIGNALS
Significant funding round ($33M) validates AI precision medicine marketSuccessful spinout demonstrates parent company's ability to incubate valuable venturesExpansion of AI-enabled diagnostic capabilities in oncologyGrowing investor confidence in precision healthcare solutions
SECTORS INVOLVED
BiotechnologyHealthcareArtificial IntelligenceDiagnosticsOncology
Analysis generated on Mar 16, 2026 at 17:11 UTC
Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by City AM. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

RELATED INTELLIGENCE

Middle East oil exports drop at least 60% as Strait of Hormuz stays mostly closed, data shows
BNN Bloomberg Mar 16, 21:13 Negative
Bell plans $1.7B AI data centre in Saskatchewan as demand for computing power surges
BNN Bloomberg Mar 16, 21:03 Positive
Urbana Corporation Intersects 4.2 g/t Au over 10 Metres and Begins Second Drill Program
BNN Bloomberg Mar 16, 20:59 Positive
Surging gas prices threaten to reverse Canada’s inflation progress, economists say
BNN Bloomberg Mar 16, 20:46 Negative
Market Outlook: Iran conflict and oil surge raise stakes before U.S. Fed
BNN Bloomberg Mar 16, 20:43 Negative